-+ 0.00%
-+ 0.00%
-+ 0.00%

IMMUNEERING ANNOUNCES NEW POTENTIALLY REGISTRATIONAL PHASE 2 TRIAL EVALUATING ATEBIMETINIB WITH CHEMOTHERAPY IN ANAPLASTIC THYROID CANCER

Reuters·11/12/2026 12:30:01

Please log in to view news